RU2016147521A - Способы применения антител к ang2 - Google Patents
Способы применения антител к ang2 Download PDFInfo
- Publication number
- RU2016147521A RU2016147521A RU2016147521A RU2016147521A RU2016147521A RU 2016147521 A RU2016147521 A RU 2016147521A RU 2016147521 A RU2016147521 A RU 2016147521A RU 2016147521 A RU2016147521 A RU 2016147521A RU 2016147521 A RU2016147521 A RU 2016147521A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- ang2
- functional part
- administered
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989884P | 2014-05-07 | 2014-05-07 | |
| US61/989,884 | 2014-05-07 | ||
| US201462005525P | 2014-05-30 | 2014-05-30 | |
| US62/005,525 | 2014-05-30 | ||
| PCT/US2015/029447 WO2015171747A1 (en) | 2014-05-07 | 2015-05-06 | Methods of using anti-ang2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016147521A true RU2016147521A (ru) | 2018-06-09 |
| RU2016147521A3 RU2016147521A3 (enExample) | 2018-12-27 |
Family
ID=54392949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147521A RU2016147521A (ru) | 2014-05-07 | 2015-05-06 | Способы применения антител к ang2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170058025A1 (enExample) |
| EP (1) | EP3139956A4 (enExample) |
| JP (1) | JP2017514854A (enExample) |
| KR (1) | KR20170003651A (enExample) |
| CN (1) | CN107206067A (enExample) |
| AU (1) | AU2015256052A1 (enExample) |
| CA (1) | CA2946906A1 (enExample) |
| HK (1) | HK1244445A1 (enExample) |
| IL (1) | IL248391A0 (enExample) |
| RU (1) | RU2016147521A (enExample) |
| SG (1) | SG11201609168PA (enExample) |
| WO (1) | WO2015171747A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| CN109863171B (zh) | 2016-08-23 | 2023-08-04 | 免疫医疗有限公司 | 抗vegf-a和抗ang2抗体及其用途 |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| WO2020175886A1 (ko) * | 2019-02-25 | 2020-09-03 | 주식회사 파멥신 | 항-ang2 항체 및 이의 용도 |
| WO2020226178A1 (ja) | 2019-05-08 | 2020-11-12 | ダイキン工業株式会社 | フルオロポリマーの製造方法及びフルオロポリマー |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2247305A4 (en) * | 2008-01-28 | 2012-11-14 | Medimmune Ltd | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| AU2011221229B2 (en) * | 2010-02-23 | 2015-06-18 | F. Hoffmann-La Roche Ag | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| CN102250247B (zh) * | 2011-06-15 | 2013-06-19 | 常州亚当生物技术有限公司 | 一种抗vegf/ang2双特异性抗体及其应用 |
| KR101607038B1 (ko) * | 2011-11-21 | 2016-04-11 | 모토로라 모빌리티 엘엘씨 | 시간 예측을 위한 병치된 픽처의 암시적 결정 및 결합된 암시적 및 명시적 결정 |
| CN104507498A (zh) * | 2012-08-07 | 2015-04-08 | 霍夫曼-拉罗奇有限公司 | 用于治疗成胶质细胞瘤的组合疗法 |
-
2015
- 2015-05-06 CA CA2946906A patent/CA2946906A1/en not_active Abandoned
- 2015-05-06 RU RU2016147521A patent/RU2016147521A/ru not_active Application Discontinuation
- 2015-05-06 SG SG11201609168PA patent/SG11201609168PA/en unknown
- 2015-05-06 KR KR1020167034326A patent/KR20170003651A/ko not_active Ceased
- 2015-05-06 AU AU2015256052A patent/AU2015256052A1/en not_active Abandoned
- 2015-05-06 WO PCT/US2015/029447 patent/WO2015171747A1/en not_active Ceased
- 2015-05-06 CN CN201580035986.9A patent/CN107206067A/zh active Pending
- 2015-05-06 EP EP15788683.9A patent/EP3139956A4/en not_active Withdrawn
- 2015-05-06 JP JP2016566641A patent/JP2017514854A/ja active Pending
- 2015-05-06 US US15/308,187 patent/US20170058025A1/en not_active Abandoned
- 2015-05-06 HK HK18103973.5A patent/HK1244445A1/zh unknown
-
2016
- 2016-10-19 IL IL248391A patent/IL248391A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3139956A4 (en) | 2017-11-29 |
| CN107206067A (zh) | 2017-09-26 |
| IL248391A0 (en) | 2016-11-30 |
| WO2015171747A1 (en) | 2015-11-12 |
| CA2946906A1 (en) | 2015-11-12 |
| US20170058025A1 (en) | 2017-03-02 |
| EP3139956A1 (en) | 2017-03-15 |
| AU2015256052A1 (en) | 2016-11-10 |
| RU2016147521A3 (enExample) | 2018-12-27 |
| HK1244445A1 (zh) | 2018-08-10 |
| JP2017514854A (ja) | 2017-06-08 |
| KR20170003651A (ko) | 2017-01-09 |
| SG11201609168PA (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016147521A (ru) | Способы применения антител к ang2 | |
| JP2017514854A5 (enExample) | ||
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| JP2017226708A5 (enExample) | ||
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| MX385320B (es) | Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas. | |
| JP2017533912A5 (enExample) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| MX2016009332A (es) | Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo. | |
| MX392618B (es) | Un anticuerpo monoclonal de anti-beta7 para usarse en el tratamiento de un trastorno inflamatorio gastrointestinal. | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA201791203A1 (ru) | ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| NZ723139A (en) | Fgf-18 compound dosing regimen | |
| RU2018127640A (ru) | Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190627 |